Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
|Videos|April 4, 2014
Photodynamic Therapy for Mesothelioma
Author(s)Todd Demmy, MD
Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, discusses photodynamic therapy for the treatment of mesothelioma.
Advertisement
Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, discusses photodynamic therapy for the treatment of mesothelioma.
Clinical Pearls:
- With photodynamic therapy, patients are given a drug that concentrates in tumor cells. A special light is then used to active the chemical, which kills the tumor cell.
- This therapy is useful for diseases that are hard to treat surgically and is currently being used to treat mesothelioma
- After a tumor is removed from a mesothelioma patient, the photodynamic agent photofrin is given to the patient and photodynamic therapy is performed to treat the microscopic cancer that is left behind
- This reduces the stress and complications of surgery that are usually associated with mesothelioma surgery
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5